Abbonarsi

Self-expandable metal stents for relieving malignant colorectal obstruction: short-term safety and efficacy within 30 days of stent procedure in 447 patients - 25/09/11

Doi : 10.1016/j.gie.2011.06.019 
Søren Meisner, MD 1, , Ferran González-Huix, MD 2, Jo G. Vandervoort, MD 3, Paul Goldberg, MD 4, Juan A. Casellas, MD 5, Oscar Roncero, MD 6, Karl E. Grund, MD 7, Alberto Alvarez, MD 8, Jesús García-Cano, MD, PhD 9, Enrique Vázquez-Astray, MD 10, Javier Jiménez-Pérez, MD 11

The WallFlex Colonic Registry Group

1 Bispebjerg Hospital, Copenhagen, Denmark 
2 Hospital Doctor Josep Trueta, Girona, Spain 
3 Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium 
4 Groote Schuur Hospital, Cape Town, South Africa 
5 Hospital General Universitario de Alicante, Alicante, Spain 
6 Hospital La Mancha Centro, Alcazar de San Juan, Spain 
7 University Hospital Tuebingen, Department of General, Visceral, and Transplantation Surgery, Tuebingen, Germany 
8 Hospital Universitario de Salamanca, Salamanca, Spain 
9 Hospital Virgen de La Luz, Cuenca, Spain 
10 Complejo Hospitalario Pontevedra, Pontevedra, Spain 
11 Hospital de Navarra, Pamplona, Spain 

Reprint requests: Søren Meisner, MD, Bispebjerg Hospital, Bispebjerg Bakke 23, entr. 7B, DK-2400 Copenhagen NV, Denmark

Riassunto

Background

The self-expandable metal stent (SEMS) can alleviate malignant colonic obstruction and avoid emergency decompressive surgery.

Objective

To document performance, safety, and effectiveness of colorectal stents used per local standards of practice in patients with malignant large-bowel obstruction to avoid palliative stoma surgery in incurable patients (PAL) and facilitate bowel decompression as a bridge to surgery for curable patients (BTS).

Design

Prospective clinical cohort study.

Setting

Two global registries with 39 academic and community centers.

Patients

This study involved 447 patients with malignant colonic obstruction who received stents (255 PAL, 182 BTS, 10 no indication specified).

Intervention

Colorectal through-the-scope SEMS placement.

Main Outcome Measurements

The primary endpoint was clinical success at 30 days, defined as the patient's ability to maintain bowel function without adverse events related to the procedure or stent. Secondary endpoints were procedural success, defined as successful stent placement in the correct position, symptoms of persistent or recurrent colonic obstruction, and complications.

Results

The procedural success rate was 94.8% (439/463), and the clinical success rates were 90.5% (313/346) as assessed on a per protocol basis and 71.6% (313/437) as assessed on an intent-to-treat basis. Complications included 15 (3.9%) perforations, 3 resulting in death, 7 (1.8%) migrations, 7 (1.8%) cases of pain, and 2 (0.5%) cases of bleeding.

Limitations

No control group. No primary endpoint analysis data for 25% of patients.

Conclusion

This largest multicenter, prospective study of colonic SEMS placement demonstrates that colonic SEMSs are safe and highly effective for the short-term treatment of malignant colorectal obstruction, allowing most curable patients to have 1-step resection without stoma and providing most incurable patients minimally invasive palliation instead of surgery. The risk of complications, including perforation, was low.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : ASA, BTS, IRB, PAL, SEMS


Mappa


 DISCLOSURE: S. Meisner is a consultant for Boston Scientific and Coloplast Denmark, and F. González-Huix is a consultant for Shering Plough. The WallFlex-eR colonic international and Spanish registries were sponsored by Boston Scientific Corporation. No other financial relationships relevant to this publication were disclosed
 The WallFlex Colonic Registry Group: Søren Meisner, MD, Bispebjerg Hospital, Copenhagen, Denmark, Ferran González-Huix, MD, Hospital Doctor Josep Trueta, Girona, Spain, Jo G. Vandervoort, MD, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium, Paul Goldberg, MD, Groote Schuur Hospital, Cape Town, South Africa, Juan A. Casellas, MD, Hospital General Universitario de Alicante, Alicante, Spain, Oscar Roncero, MD, Hospital La Mancha Centro, Alcazar de San Juan, Spain, Karl E. Grund, MD, University Hospital Tuebingen, Department of General, Visceral, and Transplantation Surgery, Tuebingen, Germany, Alberto Alvarez, MD, Hospital Universitario de Salamanca, Salamanca, Spain, Jesus García-Cano, MD, PhD, Hospital Virgen de La Luz, Cuenca, Spain, Enrique Vázquez-Astray, Complejo Hospitalario Pontevedra, Pontevedra, Spain, Javier Jiménez-Pérez, MD, Hospital de Navarra, Pamplona, Spain, Javier Barcenilla, MD, Hospital Rio Carrion, Palencia, Spain, Alessandro Repici, MD, Istituto Clinico Humanitas, Rozzano (Mi), Italy, Dimitrios Xinopoulos, MD, Saint Savas Hospital, Athens, Greece, Leopoldo Lopez-Roses, MD, Complejo Hospitalario Xeral-Calde, Lugo, Spain, Ovidio Belda, MD, Hospital Virgen del Rocio, Sevilla, Spain, Marc Giovannini, MD, Institut Paoli–Calmettes, Marseille, France, Jorge Espinós, MD, Fundacio Mutua de Terrassa, Terrassa, Spain, Ivan Garcia-Tercero, MD, Hospital Clinico San Cecilio, Granada, Spain, Guillermo Alcain, MD, Hospital Virgen de La Victoria, Malaga, Spain, Vicente Sanchiz, MD, Hospital Clinico de Valencia, Valencia, Spain, Luis Yuguero, MD, Hospital General Yague, Burgos, Spain, Antonio M. Pueyo, MD, Hospital Virgen del Camino, Pamplona, Spain, Paul Kortan, MD, St. Michael, Toronto, Canada, Truls Hauge, MD, Ullevål University Hospital, Oslo, Norway, António J. Marques, MD, De Santa Maria Epe, Lisboa, Portugal, Santiago Rodriguez, MD, Hospital Virgen de La Concha, Zamora, Spain, Francesc Vida, MD, Hospital de Manresa-Althaia, Manresa, Spain, Leopoldo Martin-Herrera, MD, Hospital Puerta del Mar, Cadiz, Spain, Antonio Naranjo, MD, Hospital Universitario Reina Sofia, Cordoba, Spain, Michael Hünerbein, MD, Helios Robert-Rössle-Klinik, Berlin, Germany, Maria Gloria Fernandez, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain, Antonio Lopez-Serrano, MD, Hospital Universitario Dr Peset, Valencia, Spain, Angelo Ferrari, MD, Instituto Paulista de Gastroenterología, São Paulo, Brazil, Blanca Ferreiro, MD, Hospital Carlos Haya, Malaga, Spain, Victor Orive, MD, Hospital de Basurto, Bilbao, Spain, Vicente Sanchiz, MD, Complejo Hospitalario de Orense, Orense, Spain, Prem Premchand, MD, Oldchurch Hospital (The New Queens Hospital), Romford, United Kingdom, Juan A. Gonzalez, Hospital Ramon Y Cajal, Majadahonda, Spain, Joyce Peetermans, PhD, Lina Ginnetti, MA, Robert Walsh, MD, Matthew Rousseau, Boston Scientific, Natick, Massachusetts, USA
 Presented at United European Gastroenterology Week, October 18-22, 2008, Vienna, Austria (Endoscopy 2008;40[suppl 1]:A6-A7).


© 2011  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 74 - N° 4

P. 876-884 - ottobre 2011 Ritorno al numero
Articolo precedente Articolo precedente
  • Usefulness of cap-assisted colonoscopy during colonoscopic EMR: a randomized, controlled trial
  • Seon-Young Park, Hyun-Soo Kim, Kyoung-Won Yoon, Sung-Bum Cho, Wan-Sik Lee, Chang-Hwan Park, Young-Eun Joo, Sung-Kyu Choi, Jong-Sun Rew
| Articolo seguente Articolo seguente
  • Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis
  • Lukejohn W. Day, Annette Kwon, John M. Inadomi, Louise C. Walter, Ma Somsouk

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.